Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: A role for β-amyloid plasma levels?

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 6, 2009, Pages 507-516

  Sobów, Tomasz ^a   Kłoszewska, Iwona ^a   Flirski, Marcin ^a   Liberski, Paweł ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alzheimer's disease; Beta amyloid; Predictors; Response; Rivastigmine

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BETA AMYLASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHENYLCARBAMATES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 75349103704     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sadik K., Wilcock G. The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17: S75-S79.
2. Gao S., Hendrie H.C., Hall K.S., et al. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998; 55: 809-815.
3. Francis P.T., Palmer A.M., Snape M., et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
5. Takeda A., Loveman E., Clegg A., et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
6. Wynn Z.J., Cummings J.L. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 100-108.
7. Lanctôt K.L., Herrmann N., Yau K.K., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-564.
8. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-327.
9. The National Institute for Health and Clinical Excellence (NICE). TA111 Alzheimer's - donepezil, galantamine, rivastigmine (review) and memantine: guidance; www.nice.org.uk/guidance/TA111/guidance/pdf/English.
10. Lanctot K.L., Herrmann N., LouLou M.M. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatr Neurosci 2003; 28: 13-26.
11. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-555.
12. Lahiri D.K., Farlow M.R., Hintz N., et al. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl 2000; 176: 60-67.
13. Racchi M., Porrello E., Lanni C., et al. Role of acetylcholinesterase inhibitors in pharmacological regulation of amyloid precursor protein processing. Aging Clin Exp Res 2006; 18: 149-152.
14. Sobow T., Kloszewska I. Short-term treatment with rivastigmine and plasma levels of Aβ peptides in Alzheimer's disease. Folia Neuropathol 2005; 43: 340-344.
15. Basun H., Nilsberth C., Eckman C., et al. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 2002; 14: 156-160.
16. Zimmermann M., Borroni B., Cattabeni F., et al. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005; 19: 237-242.
17. Sobów T., Flirski M., Kloszewska I., et al. Plasma Aβ levels as predictors of response to rivastigmine treatment in Alzheimer's disease. Acta Neurobiol Exp (Wars) 2007; 67: 131-139.
18. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
19. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
20. Neary D., Snowden J.S., Gustafson L., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
21. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
22. Sunderland T., Hill J.L., Mellow A.M., et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989; 37: 725-729.
23. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24: 637-639.
24. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
25. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
26. Sano M., Devanand D., Richards M., et al. A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease. Arch Neurol 1995; 52: 961-966.
27. Doody R.S., Hassman P., Dunn K. A method for estimating progression rates in Alzheimer Disease. Arch Neurol 2001; 58: 449-454.
28. Doody R.S., Dunn J.K., Huang E., et al. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 1-4.
29. Sobow T., Flirski M., Kloszewska I., et al. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005; 65: 117-124.
30. Chapman J., Estupinan J., Asherow A. A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996; 46: 1484-1485.
31. Davis K.L., Thal L.J., Gamzu E.R., et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253-1259.
32. Rogers S.L., Farlow M.R., Doody R.S., et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
33. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-638.
34. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449.
35. Schneider L.S., Farlow M.R. Severity of Alzheimer's disease and response to cholinergic therapy. Eur J Neurol 1996; 3: 238.
36. Kaufer D.I., Cummings J.L., Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10: 55-63.
37. Lilienfeld S., Parys W. Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 19-27.
38. Bullock R., Touchon J., Bergman H., et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-1327.
39. Motyl R., Sobów T., Ma̧czka M., et al. Badanie EX-ON: ocena tolerancji i bezpieczeñstwa stosowania riwastygminy u chorych z otȩpieniem w chorobie Alzheimera w warunkach rutynowej praktyki lekarskiej. Neurol Neurochir Pol 2005; 39 (Suppl 2): 637-638.
40. Davis K.L., Mohs R.C., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281: 1401-1406.
41. Tiraboschi P., Hansen L.A., Alford M., et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 2000; 55: 1278-1283.
42. Farlow M.R., Hake A., Messina J., et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58: 417-422.
43. Liu X., Teresi J.A., Waternaux C. Modelling the decline pattern in functional measures from a prevalent cohort study. Stat Med 2000; 19: 1593-1606.
44. Tandon R., Adak S., Kaye J.A. Neural networks for longitudinal studies in Alzheimer's disease. Artif Intell Med 2006; 36: 245-255.
45. Trinh N.H., Hoblyn J., Mohanty S., et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210-216.
46. Flirski M., Sobow T. Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2005; 2: 47-64.
47. Irizarry M.C. Biomarkers of Alzheimer disease in plasma. NeuroRx 2004; 1: 226-234.
48. Zetterberg H. Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease? Recent Pat CNS Drug Discov 2008; 3: 109-111.
49. Frankfort S.V., Tulner L.R., van Campen J.P., et al. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia. Curr Opin Pharmacol 2008; 3: 123-131.
50. Pakaski M., Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008; 53: 103-111.
51. Greig N.H., Utsuki T., Ingram D.K., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-17218.
52. Borroni B., Cociaghi F., Pastorino L., et al. Amyloid precursor protein in platelets of patients with Alzheimer's disease. Arch Neurol 2001; 58: 442-446.